Note 10. Share-based Compensation:

During the quarter ended September 30, 2022 and 2021, the Company granted 0.6 million and 0.3 million stock options at weighted average grant prices of $377.72 and $481.84 and weighted average fair values of $118.60 and $118.47, respectively. During the quarter ended September 30, 2022 and 2021, the Company granted 21,963 and 13,929 restricted stock units at a weighted average fair value of $377.52 and $481.82, respectively. During the quarter ended September 30, 2022, the Company did not grant restricted common stock shares. During the quarter ended September 30, 2021, the Company granted 5,344 shares of restricted common stock shares at a weighted average fair value of $481.82.

Stock options for 165,030 and 336,565 shares of common stock with total intrinsic values of $41.1 million and $122.8 million were exercised during the quarter ended September 30, 2022 and 2021, respectively.

Stock-based compensation expense, inclusive of payroll taxes, of $15.1 million and $13.2 million was included in selling, general and administrative expenses for the quarter ended September 30, 2022 and 2021 respectively. Additionally, the company recognized $0.3 million of stock-based compensation costs in cost of goods sold during the quarter ended September 30, 2022 compared to $0.4 million in the comparative prior year period. As of September 30, 2022, there was $85.4 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock. The weighted average period over which the compensation cost is expected to be recognized is 1.8 years.

In fiscal 2015, the Company established the Bio-Techne Corporation 2014 Employee Stock Purchase Plan (ESPP), which was approved by the Company's shareholders on October 30, 2014, and which is designed to comply with IRS provisions governing employee stock purchase plans. 200,000 shares were allocated to the ESPP. For ESPP, the Company recorded stock-based compensation expense of $0.1 million for the quarter ended September 30, 2022 and $0.3 million for the quarter ended September 30, 2021.